NEUPRO
Clinical safety rating
cautionComprehensive clinical and safety monograph for NEUPRO (NEUPRO).
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
| Metabolism | Primarily hepatic via conjugation (sulfation and glucuronidation) and N-dealkylation; CYP450 enzymes play a minor role; no major active metabolites. |
| Excretion | Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15% |
| Half-life | Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin |
| Protein binding | 99.5% bound (primarily to albumin, also to alpha-1-acid glycoprotein) |
| Volume of Distribution | 370 L (≈5.3 L/kg for 70 kg); indicates extensive tissue distribution |
| Bioavailability | Transdermal: 20-80% (mean 45%) due to variable skin permeation; relative to IV: 45% |
| Onset of Action | Transdermal: 2-6 hours (clinical effect within 24 hours; steady state by day 2-3) |
| Duration of Action | 24 hours after single application; continuous delivery over 24 hours; once-daily application recommended |
| Molecular Weight | 315.45 |
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment (CrCl >=30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) or dialysis. |
| Liver impairment | No dosage adjustment required for mild hepatic impairment (Child-Pugh A). Use with caution in moderate hepatic impairment (Child-Pugh B); no established dose modification. Not recommended in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients; off-label use not recommended. |
| Geriatric use | Initial dose 2 mg/24h; titrate slowly. Higher incidence of adverse effects (nausea, dizziness, hallucinations). Monitor renal function as age-related decline may alter clearance. |
| 1st trimester | NEUPRO (rotigotine) is a non-ergoline dopamine agonist. Data on use in the first trimester are limited. Studies in animals have shown reproductive toxicity. Avoid use unless benefits clearly outweigh risks. |
| 2nd trimester | Limited human data. In animal studies, developmental toxicity was observed. Use only if necessary and with caution. |
| 3rd trimester | Use in third trimester may cause uterine contractions or adverse effects on the fetus due to dopamine agonist activity. Avoid unless essential. Monitor for pregnancy-induced hypertension and fetal distress. |
Clinical note
Comprehensive clinical and safety monograph for NEUPRO (NEUPRO).
| Placental transfer | Rotigotine crosses the placenta in animal studies. In humans, based on molecular weight and lipophilicity, it is expected to cross the placenta. Specific human data are lacking. |
| Breastfeeding | Rotigotine is excreted into breast milk in animal studies; human data are insufficient. Based on molecular weight (about 315 Da) and potential for adverse effects (e.g., suppression of prolactin), it is recommended to avoid breastfeeding during therapy or to discontinue the drug if breastfeeding. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Pregnancy Category C. In animal studies, rotigotine caused fetal malformations at maternally toxic doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: limited data; second/third trimester: unknown risk of fetal harm. |
| Fetal Monitoring | Monitor for excessive somnolence, hypotension, and impulse control disorders in the mother. Fetal monitoring: standard prenatal care, consider ultrasound for growth if prolonged use. |
| Fertility Effects | In animal studies, rotigotine reduced fertility at high doses. Clinical effects on human fertility unknown; may cause hyperprolactinemia via dopamine agonism, potentially impairing ovulation. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to rotigotine or any component of the formulationConcomitant use of neuroleptic agents (antipsychotics) for the treatment of schizophrenia (except for clozapine) due to theoretical risk of exacerbation of psychosis
| Precautions | Sudden onset of sleep during daily activities, Symptomatic hypotension (orthostatic hypotension), Hallucinations and psychotic-like behavior, Impulse control disorders (e.g., pathological gambling, hypersexuality), Fibrotic complications (e.g., pleural effusion, retroperitoneal fibrosis), Melanoma risk (monitor skin lesions), Application site reactions (skin patch), Augmentation and rebound in RLS, Elevated blood pressure and heart rate |
| Food/Dietary | No specific food interactions; avoid alcohol as it may increase sedative effects. |
| Clinical Pearls | Apply to clean, dry, non-hairy area on upper arm, chest, abdomen, thigh, hip, or side; rotate sites daily. Avoid same site more than once every 14 days. Do not cut patch. May cause application site reactions, orthostatic hypotension, sudden sleep onset, and impulse control disorders. Taper when discontinuing. |
| Patient Advice | Apply one patch daily at the same time each day. · Choose a different application site each day; avoid the same spot for 14 days. · Do not cut the patch; apply to clean, dry, non-hairy skin. · Avoid exposing the patch to direct heat (heating pads, hot tubs, direct sunlight). · Remove the old patch before applying a new one; wash hands after. · Do not stop suddenly without consulting your doctor. · Report excessive drowsiness, sudden sleep episodes, or compulsive behaviors. · May cause dizziness or fainting; rise slowly from sitting/lying down. · Inform all healthcare providers you are using this medication. |
Loading safety data…